This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda

Similar documents
10/23/2014. Program Goals

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor

This program is supported by an educational grant from Janssen Biotech Inc, and a sponsorship from Takeda.

Understanding Inflammatory Bowel Diseases (IBD):

What is ulcerative colitis?

WHAT IS ULCERATIVE COLITIS?

I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

Ulcerative Colitis. National Digestive Diseases Information Clearinghouse. What is ulcerative colitis (UC)?

Inflammatory Bowel Diseases

Inflammatory Bowel Disease

Treatment Options. Suresh Pola, MD Kaiser San Diego

Efficacy and Safety of Treatment for Pediatric IBD

Medical therapies and IBD

Living with Ulcerative Colitis

The ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group.

Efficacy and Safety of Treatment for Pediatric IBD

What Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy?

We will discuss: Inflammatory Bowel Diseases. Life With IBD. What Are the Potential Causes of IBD?

Medical Therapy for Pediatric IBD: Efficacy and Safety

Crohn's Disease. What causes Crohn s disease? What are the symptoms?

Living with Crohn s Disease

Top 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego

Understanding IBD Medications. and Side Effects

INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE

Doncaster & Bassetlaw Medicines Formulary

Ulcerative Colitis. ulcerative colitis usually only affects the colon.

Treating Crohn s and Colitis in the ASC

IBD Module 2: Medication and Patient Management. Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics

Of Treatment For Inflammatory Bowel Diseases

Understanding Inflammatory Bowel Diseases: What Every Patient Needs to Know

Understanding IBD Medications and Side Effects

What is Inflammatory Bowel Disease (IBD)?

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

Certain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

INFLAMMATORY BOWEL DISEASE 101: From Hurdling New Diagnosis to Optimizing Treatments

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Inflammatory Bowel Disease Medical Exam Questionnaire

Outline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF

Speaker Introduction

The Road to Remission

Facts THE CROHN S COLITIS. Living Well with IBD

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION

What is Crohn's disease?

Inflammatory Bowel Disease. Your Illness and Its Treatment

Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

Living with Crohn s Disease

WHAT IF WE HAVE A FUN DAY WITHOUT UC GETTING IN THE WAY? INDICATIONS IMPORTANT RISK INFORMATION

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

PEDIATRIC INFLAMMATORY BOWEL DISEASE

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Understanding Learning is the first step to getting help.

Inflammatory Bowel Diseases Clinic

Understanding Your Benefits and Risks

The Medical Letter. on Drugs and Therapeutics. Sulfasalazine can cause reversible. therapy may be more effective Lialda (Shire)

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

Carefirst.+.V Family of health care plans

Practical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

INFLAMMATORY BOWEL DISEASE. Brittany Palasik, PharmD, BCPS University of North Texas System College of Pharmacy

Addressing Risks and Benefits In IBD

Immune Modulating Drugs Prior Authorization Request Form

Greetings, and thank you for joining us today for the Ulcerative Colitis: The A to Z of Treating UC Teleconference/Webcast.

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology

INFLAMMATORY BOWEL DISEASE

Surgical Management of IBD. Val Jefford Grand Rounds October 14, 2003

Understanding Your Benefits and Risks

Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Ulcerative colitis (UC) is a. The Patient with Newly Diagnosed Ulcerative Colitis: Anticipating the Questions and Individualizing the Answers

Staying Healthy as an IBD patient

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

Crohn s Disease. Questions & Answers

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

Guideline Ulcerative colitis: management

INFLAMMATORY BOWEL DISEASE 101: Understanding Your Child s Diagnosis

Effective Health Care Program

What is Crohn's disease?

Lupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?

Ali Keshavarzian MD Rush University Medical Center

Improving outcome of Inflammatory Bowel Disease in children

Chapter 34. Nursing Care of Patients with Lower Gastrointestinal Disorders

Inflammatory Bowel Disease

What is a Colonoscopy?

Inflectra for Crohn s disease

Wednesday, March 23, 2016

P a g e 1. Inflammatory Bowel Disease Guidelines

New Perspectives on the Diagnosis and Management of IBD. Disclosures

Transcription:

This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda

Today s Presenter Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical School

Program Goals Help you understand ulcerative colitis and its effects Review current treatments, including medications, and surgery Share resources to answer your questions and provide support

Overview of Ulcerative Colitis Type of inflammatory bowel disease (IBD) Chronic, relapsing disease of colon (large intestine) that leads to inflammation and ulceration in bowel lining About half of the cases are mild Flares may alternate with symptom-free periods Usually requires treatment to obtain and maintain remission with IBD

What Are the Potential Causes? Genetic Predisposition Environmental Factors Immune System Abnormalities

Risk Factors and Frequency Occurs at any age, often in the 30 s, with a second peak in 50 s or 60 s Affects all ethnic backgrounds; More common in Caucasians and Ashkenazi Jews Equally common in women and men Higher risk for patients with firstdegree relative with UC

Diarrhea, mixed with blood and mucous Abdominal pain and cramping Urgency to have a bowel movement Appetite loss, fatigue, weight loss May be intermittent with flare-ups Growth impairment in children Non-intestinal complications Symptoms

Disease Pattern Rectum (end part of colon) almost always involved Classified by extent of area affected Patients usually report gradual onset Recurrent attacks between periods of symptom-free remission Triggers include Psychological stress NSAIDs (e.g. Ibuprofen, naproxen) Infections (e.g, C. diff) Appendectomy and smoking appear protective from ulcerative colitis Primarily affects quality of life, not lifespan

Classification (Extent) of Ulcerative Colitis Proctitis: involvement limited to rectum Proctosigmoiditis: involves rectum and sigmoid colon (lower segment) Left-sided colitis: extends from rectum and entire left colon Pancolitis: involves the whole colon UC usually affects one continuous section of the colon beginning with the rectum. Illustration Copyright 2014 Nucleus Medical Media. All rights reserved www.nucleusinc.com.

Disease Severity Over 10 stools daily, continuous bleeding, abdominal pain, distension; systemic toxicity; potentially fatal Over 6 bloody stools daily, fever, increased heart rate, anemia, weight loss 4 6 stools daily, moderate abdominal pain, anemia Up to 4 loose stools, may be bloody; mild abdominal pain

Extra-intestinal Manifestations May include:

Extra-intestinal Manifestations May include: Eyes

Extra-intestinal Manifestations May include: Eyes Mouth

Extra-intestinal Manifestations May include: Eyes Mouth Joints

Extra-intestinal Manifestations May include: Eyes Mouth Joints Skin

Extra-intestinal Manifestations May include: Eyes Mouth Joints Skin Bones Kidneys Liver

Extra-intestinal Manifestations May include: Eyes Mouth Joints Skin Bones Kidneys Liver Vascular system

Managing your Symptoms: Treatment Options Over-the-Counter Aminosalicylates Corticosteroids Immunomodulators Biologics

Poll Question #1 My treatment regimen includes: A) Corticosteroids B) Aminosalicylates C) Immunomodulators D) Biologics E) Two or more of the above

Over-The-Counter (OTC) Medications Over-the-Counter Aminosalicylates Corticosteroids Immunomodulators Biologics Address symptoms only Anti-diarrheal agents Laxatives Pain relievers NSAIDs may cause or worsen GI irritation Talk with your physician before taking OTC meds

Aminosalicylates Over-the-Counter Aminosalicylates Corticosteroids Immunomodulators Biologics Effective for mild-moderate active disease Few serious side effects Useful in maintaining remission Medications: Sulfasalazine (Azulfadine ) Oral Olsalazine (Dipentum ) Oral Balsalazide (Colazal, Giazo ) Oral Mesalamine (Apriso, Asacol, Asacol HD, Canasa, Delzicol, Lialda, Pentasa, Rowasa ) Oral or Rectal formulations

Corticosteroids Over-the-Counter Aminosalicylates Corticosteroids Immunomodulators Biologics Moderate-to-severe disease Short-term control of flares Risks include Infection Sleep disturbance and mood swings Neurological changes Changes in physical appearance Growth delays Bone loss and fracture Medications: Budesonide (Entocort, Uceris ) Oral Hydrocortisone (Cortenema, Cortifoam ) Enema, oral, intravenous Methylprednisolone (Medrol ) Oral or intravenous Prednisone, Oral

Immunomodulators Over-the-Counter Aminosalicylates Corticosteroids Immunomodulators Biologics Steroid-sparing agents, used in maintenance Also used if no response to aminosalicylates May take 6 to 12 weeks to work Medications (oral): Azathioprine (Imuran, Azasan ) 6-mercaptopurine (Purinethol )

Over-the-Counter Aminosalicylates Corticosteroids Immunomodulators Biologics Biological Therapies Block inflammation or stimulate antiinflammation Similar to biologic chemicals in body Effective for patients who Do not respond to standard therapy No longer respond to standard therapies Maintaining remission Tapering off of steroids Medications: Anti-TNF Infliximab (Remicade ) intravenous Adalimumab (Humira ) injection Golimumab (Simponi ) injection Anti-adhesion molecule Vedolimumab (Entyvio ) intravenous

Risks of Anti-TNFs and Immunomodulators (IMs) If 10,000 patients were treated for 1 year Event Estimated Frequency NHL (baseline) 2/10,000 NHL (on IMs) 4-9/10,000 NHL (on anti-tnf with prior IMs) 4-9/10,000 Hepatosplenic T-cell lymphoma Unknown Death from sepsis (lower for younger patients) 4/1,000 Tuberculosis 5/10,000 Anti-TNF, anti-tumor necrosis factor; IMs, immunomodulators; NHL, non-hodgkin lymphoma. Table adapted from Siegel CA. In Inflammatory Bowel Disease: Translating Basic Science Into Clinical Practice. Wiley, 2010.

Treatment Goals Improve Quality of Life Disease Monitoring and Prevention Maintenance of Remission Induce remission

Location, Location, Location Rectum often responsible for most nagging symptoms Frequency Urgency Night-time bowel movements Tenesmus Rectal therapy can minimize these symptoms Enema Suppository Foam

Treatment Strategies Monotherapy Single medication treatment Combination therapy Multiple medication treatment Biologic and immunomodulator Choice of strategy dependent on Disease severity Patient s considerations Severe Moderate Mild Disease severity at presentation

Surgery Option for patients not responding to medication (less than 25% of cases) Risk of pouchitis and pouch function issues Possible approaches: Proctocolectomy Removal of entire colon Small intestine brought to abdominal wall (ostomy) Patient wears an appliance to catch waste Ileoanal anastomosis Preserves normal bowel function Creates internal pouch from small intestine; requires stages of surgery Illustration of ostomy site

Colorectal Cancer Risk UC a risk factor for colorectal cancer Increases after 8 10 years from UC onset More common as extent, length of disease and severity of UC increases Surveillance colonoscopies recommended for UC patients Recommendations At least left-sided colitis: 8 years after diagnosis Primary sclerosing cholangitis: At diagnosis Colonoscopies every 1-3 years Inflammation is risk factor for colorectal cancer; medications treating inflammation may reduce risk

Common Tests to Diagnose and Manage Ulcerative Colitis Diagnostic testing Fecal samples (presence of bacteria, parasites, markers of inflammation) Blood samples (complete blood count, inflammatory markers, liver and kidney function tests) Endoscopy Gold standard for UC diagnosis Flexible scope inserted into rectum Sigmoidoscope examines lower third of colon Colonoscope examines entire colon Biopsies taken during these procedures to examine for inflammation and pre-cancer Visual examination Radiographs (plane films) CT scans or MRI (provides more detail than x-rays) Barium enema or small bowel series

UC Impact on Quality of Life: Long-Term Medication Prescription Medications Potential Side Effects Aminosalicylates Biologics Immunomodulators Steroid (Not for maintenance treatment; 3 4 months usual limit) Over-the-Counter Medications Headache or GI upset; very rare kidney allergy, pancreatitis, pericarditis Infusion or injection site reaction, infection, skin cancer, psoriasis, lymphoma Nausea, can affect blood counts or liver tests, pancreatitis, allergy, lymphoma, skin cancer, infection Weight gain, moon face, increased blood pressure, suppressed immune system, increased infection risk Potential Side Effects Anti-diarrheals NSAIDs aspirin, ibuprofen (Advil, Motrin, others) or naproxen (Aleve) May increase risk of toxic megacolon Can cause flares or worsen symptoms (even short-term)

UC Impact on Quality of Life Examples of common challenges Unpredictable episodes of diarrhea, bleeding, cramping Sudden urgency to use restroom Temptation to avoid travel or activity Overcoming fear of being in public Maintaining social interaction to enhance self image Helpful tips Advance planning on personal supplies Know bathroom locations Exercise between flare-ups (consult your doctor) Take your medications as directed by your doctor Avoid foods that aggravate symptoms Talk to your doctor about your diet and any nutrient deficiencies

Healthcare Maintenance Vaccines Generally, follow recommended immunization schedule Some live vaccines (with active viruses) may need to be avoided in some UC patients taking: Corticosteroids Immunomodulators Biologic therapies Talk to your doctor about risks and benefits Bone care (bone density) Risk for bone loss /osteoporosis; potential factors: Corticosteroids Inflammation Vitamin D deficiency Cancer Screening Skin exams and sun block (immunomodulators and anti-tnf_ Regular pap smears (immunomodulators) Colon cancer screening Laboratory Monitoring

Strengthen Communication with Your Doctor Questions to Ask Your Doctor What parts of my bowel are affected? What treatment plan is suitable for me? What side effects from medication may occur? How soon do symptoms subside? Should I change my diet or take supplements? Would you recommend probiotics? Are there any restrictions on my activities? How often do I need a follow-up colonoscopy?

Poll Question #2 How comfortable do you feel discussing concerns about managing ulcerative colitis with your doctor? A) Very comfortable B) Comfortable C) Somewhat comfortable D) Not comfortable at all

Key Points on Ulcerative Colitis Chronic, relapsing disease of colon (large intestine) leading to inflammation and ulceration in bowel lining Symptoms and prognosis differ for each person Know the goals of your treatment strategies Talk to your doctor about monitoring your disease Prepare for your visits create checklists for your care Have open communication with your healthcare team

References References CCFA website: www.ccfa.org/resources/living-with-ulcerative-colitis.html CCFA website: www.ccfa.org/resources/types-of-medications.html Rubin, DT. Treatment Options in IBD webcast: www.ccfa.org/resources/ibd treatmentswebcast.html Understanding Ulcerative Colitis Webcast (2014)- program Co-sponsored by CCFA with AGA institute Living with Ulcerative Colitis, Patient Brochure, updated August 2014- CCFA The Facts About Inflammatory Bowel Disease, December, 2014- CCFA Additional Resources Treatment and Self-Management: http://www.ibdetermined.org/ Community Site: http://www.ccfacommunity.org/ Irwin M. and Suzanne R. Rosenthal IBD Resource Center (IBD Help Center): 888.694.8872 or info@ccfa.org Contributors Adam Cheifetz, MD- Professor of Medicine, Harvard Medical School Millie Long, MD- Assistant Professor of Medicine, UNC School of Medicine American Gastroenterological Association Institute

Question and Answer Session

CCFA Resources Irwin M. and Suzanne R. Rosenthal IBD Resource Center (IBD Help Center) M-F, 9:00 AM-5:00 PM ET Phone: 1-888-694-8872 Email: info@ccfa.org Educational webcasts: www.ccfa.org/resources/webcasts.html Connect with other patients CCFA Community website: www.ccfacommunity.org Support groups and Power of Two (peer mentors): www.ccfa.org/chapters GI Buddy Online tracking tool and mobile app www.ccfa.org/gibuddy Local educational events, visit: www.ccfa.org

Registry of patient-reported outcomes Available for pediatric and adult patients www.ccfapartners.org

AGA Resources Patient Center: www.gastro.org/patientcare/patient-center Patient guide to GI procedures: www.gastro.org/patientcare/procedures Patient guide to GI Conditions and Diseases: www.gastro.org/patientcare/conditions-diseases

Get Involved! WWW.CCTEAMCHALLENGE.ORG WWW.CCTAKESTEPS.ORG